Literature DB >> 14562580

Biliary atresia.

Barbara Anne Haber1, Pierre Russo.   

Abstract

BA is a rare disease of unclear etiology; nevertheless, its impact in the field of pediatric hepatology is significant. It is the most common surgically correctable cause of neonatal cholestasis and is the most common pediatric disease referred for liver transplantation. Little progress has been made with regard to improving outcome or understanding its pathogenesis in the past decade. Fortunately, however, a national, government-sponsored collaborative endeavor has begun that will hopefully make a significant impact upon the progress of designing new treatments for BA and develop a better understanding of its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14562580     DOI: 10.1016/s0889-8553(03)00049-9

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  16 in total

Review 1.  Zebrafish models of human liver development and disease.

Authors:  Benjamin J Wilkins; Michael Pack
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

2.  Glutathione antioxidant pathway activity and reserve determine toxicity and specificity of the biliary toxin biliatresone in zebrafish.

Authors:  Xiao Zhao; Kristin Lorent; Benjamin J Wilkins; Dylan M Marchione; Kevin Gillespie; Orith Waisbourd-Zinman; Juhoon So; Kyung Ah Koo; Donghun Shin; John R Porter; Rebecca G Wells; Ian Blair; Michael Pack
Journal:  Hepatology       Date:  2016-06-11       Impact factor: 17.425

3.  Identification of a plant isoflavonoid that causes biliary atresia.

Authors:  Kristin Lorent; Weilong Gong; Kyung A Koo; Orith Waisbourd-Zinman; Sara Karjoo; Xiao Zhao; Ian Sealy; Ross N Kettleborough; Derek L Stemple; Peter A Windsor; Stephen J Whittaker; John R Porter; Rebecca G Wells; Michael Pack
Journal:  Sci Transl Med       Date:  2015-05-06       Impact factor: 17.956

4.  Design and validation of the biliary atresia research consortium histologic assessment system for cholestasis in infancy.

Authors:  Pierre Russo; John C Magee; John Boitnott; Kevin E Bove; Trivellore Raghunathan; Milton Finegold; Joel Haas; Ronald Jaffe; Grace E Kim; Margret Magid; Hector Melin-Aldana; Frances White; Peter F Whitington; Ronald J Sokol
Journal:  Clin Gastroenterol Hepatol       Date:  2011-01-14       Impact factor: 11.382

5.  DNA hypomethylation causes bile duct defects in zebrafish and is a distinguishing feature of infantile biliary atresia.

Authors:  Randolph P Matthews; Steven F Eauclaire; Monica Mugnier; Kristin Lorent; Shuang Cui; Megan M Ross; Zhe Zhang; Pierre Russo; Michael Pack
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

6.  Interferon-gamma directly mediates developmental biliary defects.

Authors:  Shuang Cui; Steven F Eauclaire; Randolph P Matthews
Journal:  Zebrafish       Date:  2013-02-28       Impact factor: 1.985

7.  The use of Yes-associated protein expression in the diagnosis of persistent neonatal cholestatic liver disease.

Authors:  Grzegorz T Gurda; Qingfeng Zhu; Haibo Bai; Duojia Pan; Kathleen B Schwarz; Robert A Anders
Journal:  Hum Pathol       Date:  2014-01-23       Impact factor: 3.466

8.  Extrahepatic cholangiocyte cilia are abnormal in biliary atresia.

Authors:  Sara Karjoo; Nicholas J Hand; Lorena Loarca; Pierre A Russo; Joshua R Friedman; Rebecca G Wells
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-07       Impact factor: 2.839

9.  Rargb regulates organ laterality in a zebrafish model of right atrial isomerism.

Authors:  Maija K Garnaas; Claire C Cutting; Alison Meyers; Peter B Kelsey; James M Harris; Trista E North; Wolfram Goessling
Journal:  Dev Biol       Date:  2012-09-13       Impact factor: 3.582

10.  Synthesis and Structure-Activity Relationship Study of Biliatresone, a Plant Isoflavonoid That Causes Biliary Atresia.

Authors:  Michelle A Estrada; Xiao Zhao; Kristin Lorent; Alyssa Kriegermeier; Seika A Nagao; Simon Berritt; Rebecca G Wells; Michael Pack; Jeffrey D Winkler
Journal:  ACS Med Chem Lett       Date:  2017-12-14       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.